Regeneron Pharmaceuticals Inc

24 ago 2026, 23:36 UTC

Regeneron Pharmaceuticals shares are slightly higher in after-market hours, reaching a high of 1.09% above Monday's close. No specific news was identified for the move.

21 ago 2026, 23:46 UTC

Regeneron Pharmaceuticals Inc is trading lower in after-market hours, reflecting a slight decline since Friday's close, with no specific news identified.

20 ago 2026, 23:26 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, maintaining a strong position above the 20-day moving average and near the one-month range.

19 ago 2026, 20:02 UTC

Regeneron Pharmaceuticals gained FDA approval for Pasatru, a treatment for a rare genetic disorder. Shares are advancing, reflecting strong investor sentiment.

13 ago 2026, 19:16 UTC

Regeneron Pharmaceuticals is trading higher as social media highlights REGN17235's potential in ongoing clinical trials, supporting strong performance since Wednesday's close.

12 ago 2026, 23:01 UTC

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements regarding its Phase III Fianlimab-Libtayo Study, contributing to lower after-market trading.

11 ago 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market hours. No specific company news was identified to explain this movement.

10 ago 2026, 20:02 UTC

Regeneron Pharmaceuticals Inc shares are higher, supported by broader market strength and reduced expectations for Federal Reserve interest rate hikes following Friday's jobs report.

7 ago 2026, 22:16 UTC

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and unlawful business practices.

6 ago 2026, 19:26 UTC

Regeneron Pharmaceuticals faces a potential class action lawsuit over alleged securities fraud, contributing to a decline in shares despite receiving Health Canada approval for Libtayo.

5 ago 2026, 20:06 UTC

Regeneron Pharmaceuticals is trading higher, reflecting gains since Tuesday, amid a decline in crude oil prices that eases inflationary pressures.

4 ago 2026, 23:46 UTC

Regeneron Pharmaceuticals is roughly flat in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

3 ago 2026, 19:46 UTC

Regeneron Pharmaceuticals faces class action lawsuits over alleged securities fraud related to its Phase III Fianlimab-Libtayo Study, contributing to lower share prices.

1 ago 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

31 lug 2026, 23:06 UTC

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

30 lug 2026, 19:49 UTC

Regeneron Pharmaceuticals is trading higher, significantly above its 20-day moving average and near the upper end of its one-month trading range.

29 lug 2026, 23:16 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining strength above the 20-day moving average despite broader market caution over rising interest rates.

28 lug 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc is higher in after-hours trading, continuing its positive momentum and remaining above its 20-day moving average. No specific news was identified.

27 lug 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

25 lug 2026, 00:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

24 lug 2026, 20:13 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

23 lug 2026, 09:56 UTC

Regeneron Pharmaceuticals Inc shares are modestly higher in pre-market trading. No specific company news was identified to explain the price movement.

22 lug 2026, 23:46 UTC

Regeneron Pharmaceuticals shares are higher in after-hours trading, peaking post-market despite cautious sentiment from rising crude oil prices and geopolitical tensions.

21 lug 2026, 23:51 UTC

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

17 lug 2026, 19:26 UTC

Regeneron Pharmaceuticals faces a class action lawsuit from Levi & Korsinsky, LLP, contributing to ongoing declines in the stock amid market volatility.

16 lug 2026, 20:03 UTC

Regeneron Pharmaceuticals is trading higher, supported by gains in the Biotechnology sub-sector amid a strong broader market performance today.

15 lug 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are higher Wednesday, recovering from an earlier dip and remaining above the 20-day moving average. No specific news was identified.

13 lug 2026, 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

11 lug 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

10 lug 2026, 19:26 UTC

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.